Abstract
Thorotrast is a colloidal suspension of thorium dioxide that was used as an intravascular contrast agent until the 1950’s. It is retained by the reticuloendothelial system, and because it emits densely ionizing radioactivity thorium dioxide it is carcinogenic. Two patients with prior thorium dioxide exposure diagnosed with cholangiocarcinoma and recently treated at the Massachusetts General Hospital are presented. Radiology, treatment, pathologic findings, and relevant literature are discussed.
Similar content being viewed by others
Author information
Authors and Affiliations
About this article
Cite this article
Zhu, A., Lauwers, G. & Tanabe, K. Cholangiocarcinoma in association with Thorotrast exposure. J Hepatobiliary Pancreat Surg 11, 430–433 (2004). https://doi.org/10.1007/s00534-004-0924-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00534-004-0924-5